FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134811541> ?p ?o ?g. }

• W2134811541 endingPage "26" @default.
• W2134811541 startingPage "21" @default.
• W2134811541 abstract "ABSTRACT Introduction Invasive sinus aspergillosis infection has been reported with increasing frequency in the last decade, especially, in immunocompromised patients with chronic invasive sinus aspergillosis (CISA). The gold standard for treatment has been wide surgical debridement, intravenous administration of antifungal agents, such as amphotericin B, but the prognosis remains poor. Newer antifungal agents are being tried but no standard treatment option with new antifungal agents has yet been established for chronic invasive fungal sinusitis. Therefore, we undertook this study to evaluate the efficacy of voriconazole in patients of chronic invasive sinus aspergillosis. Materials and methods This study is a prospective randomized unblinded study with primary aim of evaluating the feasibility and effectivity of voriconazole in patients of chronic invasive sinus aspergillosis with intraorbital or intracranial extension, and secondarily to compare voriconazole with amphotericin B therapy in patients with chronic invasive sinus aspergillosis. Observations and results Thirty-three patients who fulfilled the eligibility criteria were included in this study. There were 18 patients enrolled in group I who received amphotericin therapy and 15 patients in group II who received voriconazole therapy. Out of 33 patients, 9 patients had complete response, 10 had partial response, in eight patients disease became stable and there were seven failures. Overall 50% patients had a successful outcome in group I, whereas 60% had a successful outcome in group II receiving oral voriconazole. On comparing only in extradural group, 5/10 had a successful outcome in group I receiving amphotericin B, whereas 8/12 (66.7%) had a successful outcome in group 2 receiving voriconazole. There was significant difference between adverse reactions of the two drugs, with amphotericin B having a significant renal and cardiotoxicity as compared to voriconazole; though patients on voriconazole developed skin rashes which were transient and disappeared on completion of the therapy. Conclusion The present series demonstrates that oral voriconazole can be the primary line of therapy in chronic invasive sinus aspergillosis in carefully monitored immunocompetent cases. Multicentric, randomized studies are required to define disease definition, duration and successful outcome." @default.
• W2134811541 created "2016-06-24" @default.
• W2134811541 date "2011-01-01" @default.
• W2134811541 modified "2023-10-14" @default.
• W2134811541 title "Should Voriconazole be the Primary Therapy for Chronic Invasive Sinus Aspergillosis (CISA)?" @default.
• W2134811541 cites W1993261793 @default.
• W2134811541 cites W1995296802 @default.
• W2134811541 cites W2008145508 @default.
• W2134811541 cites W2016475773 @default.
• W2134811541 cites W2030215735 @default.
• W2134811541 cites W2065304933 @default.
• W2134811541 cites W2066349230 @default.
• W2134811541 cites W2075583715 @default.
• W2134811541 cites W2080435412 @default.
• W2134811541 cites W2082695689 @default.
• W2134811541 cites W2108737854 @default.
• W2134811541 cites W2129795992 @default.
• W2134811541 cites W2159660164 @default.
• W2134811541 cites W4230924492 @default.
• W2134811541 cites W4245611019 @default.
• W2134811541 cites W4253083258 @default.
• W2134811541 cites W64071457 @default.
• W2134811541 doi "https://doi.org/10.5005/jp-journals-10013-1065" @default.
• W2134811541 hasPublicationYear "2011" @default.
• W2134811541 type Work @default.
• W2134811541 sameAs 2134811541 @default.
• W2134811541 citedByCount "2" @default.
• W2134811541 countsByYear W21348115412012 @default.
• W2134811541 crossrefType "journal-article" @default.
• W2134811541 hasBestOaLocation W21348115411 @default.
• W2134811541 hasConcept C126322002 @default.
• W2134811541 hasConcept C141071460 @default.
• W2134811541 hasConcept C157369684 @default.
• W2134811541 hasConcept C16005928 @default.
• W2134811541 hasConcept C203014093 @default.
• W2134811541 hasConcept C2776391196 @default.
• W2134811541 hasConcept C2776407911 @default.
• W2134811541 hasConcept C2779548794 @default.
• W2134811541 hasConcept C2779629538 @default.
• W2134811541 hasConcept C2780690907 @default.
• W2134811541 hasConcept C59822182 @default.
• W2134811541 hasConcept C71924100 @default.
• W2134811541 hasConcept C86803240 @default.
• W2134811541 hasConceptScore W2134811541C126322002 @default.
• W2134811541 hasConceptScore W2134811541C141071460 @default.
• W2134811541 hasConceptScore W2134811541C157369684 @default.
• W2134811541 hasConceptScore W2134811541C16005928 @default.
• W2134811541 hasConceptScore W2134811541C203014093 @default.
• W2134811541 hasConceptScore W2134811541C2776391196 @default.
• W2134811541 hasConceptScore W2134811541C2776407911 @default.
• W2134811541 hasConceptScore W2134811541C2779548794 @default.
• W2134811541 hasConceptScore W2134811541C2779629538 @default.
• W2134811541 hasConceptScore W2134811541C2780690907 @default.
• W2134811541 hasConceptScore W2134811541C59822182 @default.
• W2134811541 hasConceptScore W2134811541C71924100 @default.
• W2134811541 hasConceptScore W2134811541C86803240 @default.
• W2134811541 hasIssue "1" @default.
• W2134811541 hasLocation W21348115411 @default.
• W2134811541 hasOpenAccess W2134811541 @default.
• W2134811541 hasPrimaryLocation W21348115411 @default.
• W2134811541 hasRelatedWork W1484577646 @default.
• W2134811541 hasRelatedWork W184976125 @default.
• W2134811541 hasRelatedWork W1977881225 @default.
• W2134811541 hasRelatedWork W1987003020 @default.
• W2134811541 hasRelatedWork W2093979994 @default.
• W2134811541 hasRelatedWork W2162514903 @default.
• W2134811541 hasRelatedWork W2166327503 @default.
• W2134811541 hasRelatedWork W2396937447 @default.
• W2134811541 hasRelatedWork W2587897283 @default.
• W2134811541 hasRelatedWork W64071457 @default.
• W2134811541 hasVolume "4" @default.
• W2134811541 isParatext "false" @default.
• W2134811541 isRetracted "false" @default.
• W2134811541 magId "2134811541" @default.
• W2134811541 workType "article" @default.